Elevance Health (ELV) is reportedly increasing its dividend to $1.71 twice. The company has been facing a mixed bag of challenges but has managed to keep trading at depressed levels. It is mentioned that trading in
Elevance five and 20 years ago would have delivered noticeable gains to investors.
ELV has been named as one of the best health insurance stocks to buy in 2025 despite it seeing a 15% fall in its stock price. Interestingly, the rumors suggest that Alphabet's Verily is selling its Granular insurance business to Elevance.
Elevance stock has seen a rollercoaster of activities in Q4 with its revenue hitting $45B despite a fall in Medicaid memberships. It reported quarterly earnings that beat estimates and raised its dividends by 5%. However, it also reported a significant earnings plunge due to persistently high medical costs. The company has faced Medicaid redetermination strikes that led to an earnings miss. Still, its managed care kept impressing and inspite of the fall stocks returned slightly after the dividend was raised.
Looking beyond the current issues, Elevance appears to be a potentially lucrative purchase as its diversified revenue streams in health insurance are impressive. Despite its struggles with Medicaid, overall, it reported strong 2024 results and a positive 2025 outlook.
Elevance Health ELV News Analytics from Wed, 17 Jul 2024 07:00:00 GMT to Fri, 21 Feb 2025 19:00:00 GMT -
Rating 3
- Innovation 8
- Information 6
- Rumor -6
